15 results about "Multikinase inhibitor" patented technology

Compositions and methods for inducing pterygium regression from visual axis / central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.

The invention discloses a colorectal cancer treatment effect evaluation method, system and equipment based on SPP1 + TAMs. According to the application, the high heterogeneity of the TAM in the colorectal cancer and the metastatic microenvironment thereof is systematically revealed from three dimensions of spatial distribution, metabolic characteristics and functional states. On the basis, the invention provides a method for evaluating the treatment effect of the multi-kinase inhibitor and / or the anti-PD-1 therapy medicine on the colorectal cancer based on SPP1 + TAMs, a medicine screening method, a system, equipment and the like, so that a doctor is assisted in evaluating the treatment effect of a patient suffering from the colorectal cancer, and a clinician is guided to formulate an individualized treatment scheme for the patient; meanwhile, a new thought is provided for treatment of colorectal cancer.

A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, multi-phase modulator, or multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib.

The present invention belongs to the field of pharmaceutical technology and relates to a novel use of a multikinase inhibitor. Specifically, it relates to a compound represented by formula (I) for treating biliary tract cancer, or a pharmaceutically acceptable salt, stereoisomer, or crystalline form thereof, and a drug composition containing the same. It also relates to a method for treating biliary tract cancer using the same, a use for treating biliary tract cancer, and a use in manufacturing a drug for treating biliary tract cancer. The definitions of each variable in the above formula are as defined in the specification. Research results reveal that a multikinase inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt, stereoisomer, or crystalline form thereof has a therapeutic role against biliary tract cancer, and is considered to have very great potential for clinical application, particularly as it has a significant therapeutic role against cholangiocarcinoma.

Provided are compounds of formula (I), tautomers thereof, deuterated derivatives of the compounds or tautomers, and pharmaceutically acceptable salts of the foregoing, compositions comprising compounds of formula (I), tautomers thereof, deuterated derivatives of the compounds or tautomers, and / or pharmaceutically acceptable salts of the foregoing, and methods of using same in treating diseases, disorders, or conditions mediated by inhibition of protein kinases such as, for example, hematopoietic progenitor kinase 1 (HPK1, MAP4K1), human Fms-like tyrosine kinase 3 receptor (FLT3), and Aurora kinase. JPEG2025525278000046.jpg39170

Provided are a liver cell cancer therapeutic agent, a therapeutic method, etc., which can exhibit more potent and sustained antitumor effects than a conventional multi-kinase inhibitor. The present invention is characterized by including, as a combination medicament for treating liver cell cancer: a lenvatinib or a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; and an antibody against human DLK-1 having an in-vivo anti-tumor activity or antibody fragments derived from said antibody.

The subject matter described herein is directed to compositions comprising a MEK inhibitor, or a pharmaceutically acceptable salt thereof, and a multi-kinase inhibitor that targets PDGFRα, S6 and STAT3 or a pharmaceutically acceptable salt thereof, and their use in treating pancreatic cancer. In another aspect, disclosed herein are methods of treating pancreatic cancer by administering a MEK inhibitor, or a pharmaceutically acceptable salt thereof, and a multi-kinase inhibitor, or a pharmaceutically acceptable salt thereof. In another aspect, the combination of cobimetinib, or a pharmaceutically acceptable salt thereof, and ponatinib or a pharmaceutically acceptable salt thereof is administered in a composition or the combination is administered separately to treat pancreatic cancer.

Provided are compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing, compositions comprising the compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the foregoing, and methods of using the same, in treating, for example, the diseases, disorders, or conditions mediated by the inhibition of protein kinases, such as Hematopoietic progenitor kinase 1 (HPK1, MAP4K1), Human Fms-like tyrosine kinase 3 receptor (FLT3), and Aurora kinases.

The invention provides a pharmaceutical composition and application thereof in preparation of a medicine for treating liver cancer. It is found for the first time that when oral small-molecule multi-kinase inhibitor sorafenib and deubiquitinase USP2 inhibitor ML364 for treating liver cancer are combined for use, hepatoma cell ferroptosis can be obviously induced, sensitivity of hepatoma cells to sorafenib is improved, and therefore the progress of liver cancer is effectively inhibited. The pharmaceutical composition provided by the invention has a wide application prospect in preparation of medicines for treating liver cancer.

To provide appropriate treatment for liver cancer patients, we offer indicators of sensitivity to multi-kinase inhibitors. [Solution] The present invention provides a testing method, testing apparatus, and testing program that use the fat content in liver cancer tissue as an indicator of sensitivity to multi-kinase inhibitors. This makes it possible to predict the therapeutic effect of multi-kinase inhibitors and provide appropriate treatment to individual liver cancer patients. The fat content can be calculated from images of liver cancer tissue or signals for image display. Images include MRI images, CT images, ultrasound images, stained images of tissue biopsies, etc. Signals for image display include MR signals, etc. Examples of multi-kinase inhibitors include lenvatinib and sorafenib.

To provide an ophthalmic composition and a method for treating primary and recurrent pterygium.SOLUTION: Compositions and methods for inducing pterygium regression from the visual axis / central cornea, for stabilizing pterygium, for treating hyperemia and symptoms in pterygium patients, and for treating pterygium recurrence after pterygiectomy are disclosed. The methods include administering a multikinase inhibitor, an antimetabolite, or a combination thereof to a patient in need of the method.SELECTED DRAWING: None

Disclosed are compositions and methods for inducing pterygium regression from the visual axis / corneal center, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence after pterygium resection. The method comprises administering a multi-kinase inhibitor, an antimetabolite, or a combination thereof to a patient requiring the method.

The present invention provides compositions and methods for inducing pterygium regression from the visual axis / corneal center, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence after pterygium excision. [Solution] A method for inducing pterygium regression from the visual axis / corneal center, comprising administering a therapeutically effective amount of (1) a multikinase inhibitor; (2) an antimetabolite that inhibits epithelial cell proliferation and fibroblast proliferation; or (3) a combination thereof to the affected eye of a subject requiring treatment.

Immunotherapies, particularly chimeric antigen receptors (CARs) targeting GRP78, and their use for treating cancer are provided. Also provided are nucleic acids encoding the CARs, vectors including the nucleic acids encoding the CARs, and immune cells expressing the CARs. Also provided are methods of treating a subject with cancer, including administering to the subject a GRP78 immunotherapy and a combination chemotherapy including a HSP90 inhibitor and a multikinase inhibitor.